ProQR Therapeutics NV:AX-422 针对MPS1的临床试验申请预计2027年初提交 初步数据有望于2027年上半年出炉

美股速递
Jun 25

ProQR Therapeutics NV 宣布,其针对黏多糖贮积症I型(MPS1)的研究性疗法AX-422,预计将于2027年初提交临床试验申请(CTA)。公司进一步表示,该试验的初步数据有望在2027年上半年获得。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10